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Global trends in the prevalence of overweight and obesity put the adipocyte in the 
focus of huge medical interest. This review highlights a new topic in adipose tissue 
biology, namely the emerging pathogenic role of fat accumulation in bone marrow 
(BM). Specifically, we summarize current knowledge about the origin and function of 
BM adipose tissue (BMAT), provide evidence for the association of excess BMAT with 
diabetes and related cardiovascular complications, and discuss potential therapeutic 
approaches to correct BMAT dysfunction.There is still a significant uncertainty about 
the origins and function of BMAT, although several subpopulations of stromal cells 
have been suggested to have an adipogenic propensity. BM adipocytes are higly 
plastic and have a distinctive capacity to secrete adipokines that exert local and 
endocrine functions. BM adiposity is abundant in elderly people and has therefore 
been interpreted as a component of the whole-body ageing process. BM senescence 
and BMAT accumulation has been also reported in patients and animal models with 
type 2 diabetes, being more pronounced in those with ischaemic complications. 
Understanding the mechanisms responsible for excess and altered function of BMAT 















Body fat exerts vital regulatory roles in systemic metabolic homeostasis, functioning as 
an energy storage organ (1) and a paracrine and endocrine entity regulating the function 
of neighbouring cells as well as influencing distant organs and tissues.(2-4)  
During the development of obesity, adipose tissue expands through increases in cell 
number (adipocyte hyperplasia) and size (adipocyte hypertrophy). Fat accumulation is 
often associated with the acquisition of a pathogenic phenotype, for which the term 
“adiposopathy” has been coined.(5) Sick fat contributes to systemic inflammation, insulin 
resistance, and lipid accumulation in the liver and cardiovascular tissue (6-9)  Research 
has mainly focused on the opposing influences of visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) in these processes.(10, 11) 
The observation that human bone marrow (BM) contains fat cells dates to over a 
century ago. Surprisingly, BM adipose tissue (BMAT) has attracted much less clinical 
attention than classical fat storing tissues. In the last 20 years, however, there has been 
an increasing number of publications on BMAT. Searching for “bone marrow fat tissue”, 
on PubMed, we retrieved 36 publications in year 2000; these increased sharply until 
2014 (n=353) remaining stable to the present time. The first international meeting on 
BMAT was held in Lille, France, in 2015. Successful follow-up meetings culminated in 
the creation of a new scientific society, the International Bone Marrow Adiposity Society 
(BMAS, http://bma-society.org/), with the ambition to network and promote an 
interdisciplinary approach to the study of this emerging tissue. One important milestone 
of the BMAS has been the publication of guidelines for the standardisation, 
nomenclature, and harmonisation in BM adiposity research.(12) 
Despite the growing interest on BMAT, there are still controversies regarding the 
relevance of this fat depot in the pathophysiology of diabetic cardiovascular 




remodelling in diabetes is also missing. Therefore, the overall scope of this review article 
is to put the BMAT into a more precise pathophysiology context, both at local and 
systemic level. 
The review has three specific objectives: (1) Summarize current knowledge about 
the origin and function of BMAT and its association or direct contribution in a variety of 
pathological processes. (2) Provide evidence for the association of excess BMAT with 
diabetes mellitus and related cardiovascular complications. (3) Discuss potential 
therapeutic approaches to preserve BM function and whole-body health. 
Review purpose 1: Current knowledge about the origin and function of BM 
adipose tissue  
An extensive review of this topic has been provided by three recent publications. (13-
15) Here, we summarize the most important concepts as a basis for subsequent 
interpretation of studies on the impact of diabetes on BMAT. 
• Assessment, characterisation, and imaging of BMAT. Various analytic methods 
are available to study BMAT. Histology is a standard approach to determine adipocyte 
size and the association with other marrow cells, but is not suitable to assess the 
absolute volume of fat and can be affected by bias due to anatomical heterogeneity.(16) 
New flow cytometry methods have resolved the problems associated with the large 
volume and frailty of adipocytes as well as lipoprotein clogging in the apparatus.  It is 
now possible to use flow cytometry to distinguish adipocyte subpopulations with high 
precision.(17). Sorting methods have been also improved with resolution at a single cell 
level (18, 19) Recently, Schwalie and colleagues have performed single-cell RNA 
sequencing to determine the diversity of gene expression in each cell.(20) Using 
bioinformatic approaches, they identified two major adipocyte populations associated 
with stemness or the early steps of adipocyte formation. A rarer population was 




single-cell RNA sequencing studies to define the heterogeneity and adipogenic 
commitment of BM cells. Tikhonova et al have mapped the transcriptional landscape of 
mouse BM vascular, perivascular, and osteoblast cell populations at single-cell 
resolution, under normal conditions and following stress-induced haematopoiesis. This 
analysis demonstrated a dynamic and heterogeneous molecular landscape of the BM 
niche, including an adipocytic skewing of perivascular cells in conditions of stress (21)  
Imaging methodologies to visualize and quantify the BMAT in vivo include proton 
magnetic resonance spectroscopy, magnetic resonance imaging (MRI) (22-24) and 
osmium-based μCT.(25, 26) 
• Origin of BM adipocytes. Lineage tracing studies indicate BM adipocytes derive 
from resident mesenchymal progenitor cells,(27, 28) renamed recently as skeletal stem 
cells,(29) which also have osteo/chondrogenic potential.(30, 31) Although osteoporosis 
often associates with BMAT accumulation, recent work indicated the latter can develop 
in the setting of preserved or increased bone density.(32-34) This observation suggests 
the existence of distinctive populations of stromal cells specifically committed to 
differentiate into osteoblasts and chondrocytes, or adipocytes. Candidate adipogenic 
populations comprise perisinusoidal mesenchymal cells expressing the leptin receptor 
(Lepr) and platelet-derived growth factor receptor α (35-37), the chemokine (C-X-C 
motif) ligand 12 (CXCL12), (38) or neural/glial antigen 2 and nestin.(39) On the other 
hand, expression of the bone morphogenetic protein antagonist gremlin 1 defines a 
population of BM osteo-chondro-reticular stem cells, endowed with capacity to self-
renew and generate osteoblasts and chondrocytes, but not adipocytes.(40) 
• Comparison of BMAT with other fat depots. Adipocytes from classical depots 
have been divided into two subtypes derived from distinct precursors (Figure 1A). The 
first subtype consists of unilocular white adipocytes that derive from Pax7–/Myf5– stromal 




excessive energy supply in a triglyceride droplet and release fatty acids in periods of 
energy depletion. In addition, white adipocytes exert endocrine activity through the 
secretion of adipokines that regulate metabolism and inflammation. The second subtype 
comprise thermogenic brown adipocytes and beige adipocytes. They derive from 
Pax7+/Myf5+ stromal cells, are multilocular, rich in mitochondria, and highly specialized 
in dissipating stored energy in the form of heat through a mitochondrial mechanism 
involving the uncoupling protein-1 (UCP-1). For the sake of conciseness, we refer the 
reader to a recent review about the similarities and distinct features of white, brown and 
beige adipocytes.(41) 
BMAT shares some phenotypic similarities with but constitutes a distinct category 
from both white and brown adipose tissue. In term of morphological features, BM 
adipocytes tend to be smaller than those in other depots are, are filled with a large 
unilocular lipid vacuole, a typical feature of white adipocytes, but appear isolated and 
scattered among haematopoietic cells, which is a striking difference compared with well-
packed adipocytes forming subcutaneous or visceral fat lobules (Figure 1B).(4, 42, 43) 
The molecular phenotype of BM adipocytes reportedly varies according to the 
localisation. In the long bones, they show gene expression features typical of the white 
lineage, whereas in the vertebrae brown-like thermogenic characteristics seemingly 
prevail. (4) Differences are also known regarding functional modulation by aging, caloric 
and amino acid intake, and cold or beta-adrenergic stimulation (Table 1).(44)  
• BMAT plasticity. A distinction has been proposed for the existence of constitutive 
and regulated BMAT (Figure 1C). The former appears early during postnatal 
development in distal skeletal regions including the hands, feet, distal tibia and tail (in 
rodents). The latter accumulates in areas of red, haematopoietic marrow throughout life 
and changes in quantity and quality in response to environmental or pathological 




larger animal species, where the two subtypes tend to overlap. Moreover, constitutive 
BMAT contains more unsaturated lipids than the regulated BMAT in proximal/central 
skeletal regions.(26) 
In an adult subject weighing 65 kg, the average weight of BM is about 2.6 kg, of 
which half is fat tissue. In the same individual, total body fat is about 10 kg; hence, BMAT 
is estimated to be 10-15% of the total fat mass.(4, 46) BMAT increases with ageing more 
sharply in female subjects between 55 and 65 years of age, while male subjects continue 
to increase marrow fat at a more gradual steady rate.(30, 47, 48)  
• Molecular regulators of adipocyte turnover. The increase of fat mass in obesity 
and diabetes is attributed to two mechanisms: adipocyte hypertrophy, the process where 
pre-existing fat cells increase in size due to lipid accumulation, and adipocyte 
hyperplasia, occurring through differentiation from preadipocytes. Preadipocytes are 
replicative cells, but they are also committed to differentiation under the regulatory 
influence of a cascade of transcription factors, which cause growth arrest and promote 
adipogenesis. (49)   Adipocytes are instead considered terminally differentiated cells, 
though recent research suggests that a low level of turnover occurs at this cellular 
level.(50-52) Moreover, aged adipocytes can be cleared through apoptosis.(53) 
Activation of adipocyte apoptosis/necrosis could result in increased blood lipid 
concentrations, ectopic lipid storage and detrimental metabolic effects.(54) 
 In peripheral fat, preadipocyte differentiation is regulated by transcription factors 
with most belonging to the C2H2‐type zinc finger and HOX families,(55) and including 
the peroxisome proliferator-activated receptor γ (PPARγ).(56) These work together, 
directly or indirectly, to regulate the expression of hundreds of downstream protein‐
coding genes and noncoding RNAs responsible for adipogenesis. (57)  
 The molecular machinery controlling adipocyte turnover in BM is not different from 




the leptin-dependent activation of a downstream signaling encompassing Jak2/Stat3 
and Cebpα.(59) This mechanism was verified by investigating mice with conditionally 
deleted leptin receptor and using Jak2/Stat3 inhibitors, which  blocked the effect of leptin 
on preadipocyte differentiation. (59) In contrast, the mechanisms triggering BMAT 
apoptosis and the contribution of BMAT in increasing blood lipid concentrations have 
not been deeply explored as for other tissue depots.  
• Putative BMAT functions and implication in disease states. BMAT plays 
functional roles in energy storage, bone metabolism, and haematopoiesis and exerts 
systemic endocrine effects. Here, we will discuss the aspects in relation to health and 
disease, while the implication for obesity and diabetes is discussed in a subsequent 
section.  
Energy storage. Lipids released by BM adipocytes represent a fuel source for 
neighbouring cells, including for bone and haematopoietic cells.(60) When cellular 
energy is requested, either by the BM adipocytes themselves or neighbouring cells, lipid 
droplets are broken down to free fatty acids through lipolysis. This process is regulated 
in a way like other adipose depots, but responsiveness to stimuli can be different, for 
instance following beta-adrenergic stimulation.(61) Implication in disease states: BMAT 
induced lipolysis is exploited by proliferating neoplastic cells thereby facilitating cancer 
spreading. For instance, BM adipocytes reportedly transfer lipids to leukemic cells; 
contrasting this mechanism can be useful to inhibit cancer growth.(62-64) 
Haematopoiesis. A keystone contribution from Naveiras et al. reported BM 
adipocytes act as negative regulators of the haematopoietic microenvironment.(16). 
However, contrasting findings have been reported in humans and animal models and 
even in different anatomical locations in the same individual, suggesting a complex 
interplay between BM adipocytes and haematopoietic cells.(65-69) Implication in 




pattern of peripheral to central replacement of the haematopoietic component with 
adipose tissue.(60) Excessive expansion and dysfunction of BMAT, as in aging, obesity, 
or exogenous adipocyte transplantation, reportedly results in inhibition of 
haematopoiesis, and bone frailty. (30, 70) BMAT accumulation in aging mice and 
humans is associated with an inflammatory environment referred to as 
inflammaging.(71) Increased levels of inflammatory cytokines, including IL-1, IL-6, and 
TNFα, found in aged BM, can negatively regulate B lymphopoiesis, and enhance 
myelopoiesis. Early arrest of B lymphopoiesis in rabbit BM corresponds with increases 
in fat and myeloid cells, through a mechanism involving inflammatory molecules IL-1β 
and S100A9.(72) The inhibition of B lymphopoiesis by adipocytes could be partially 
prevented by an inhibitor of the NLRP3 inflammasome.(72) 
Endocrine functions. A recent review by Li et al. summarized the endocrine functions 
of BMAT.(46) BM adipocytes release different molecules either in a soluble form or 
packaged in microvesicles and exosomes.(73, 74) Although an overlap exists in the 
adipokine repertoire with other fat depots, BMAT surpasses the more widespread WAT 
as a source of adiponectin.(75) Moreover, BMAT secretes an extensive number of 
cytokines, such as leptin, resistin, and C-C Motif Chemokine Ligand 2 (CCL2).(76, 77) 
Implication in disease states: Mounting evidence indicates that paracrine/endocrine 
activity of BMAT is altered in myeloproliferative disease and can favour metastatic 
tumour growth in the bone through induction of a local inflammatory microenvironment 
(77-80)  
Review purpose 2: Association of excess BMAT with diabetes and related 
cardiovascular complications.  
Excess VAT is widely acknowledged to be a pathogenic factor in the metabolic 




association between BMAT, diabetes, and cardiovascular disease is still matter of 
debate.  
• Data regarding BMAT expansion. Several studies investigated BMAT in type 2 
diabetes with conflicting results. Sheu reported an increased adiposity in the vertebral 
marrow of 38 older diabetic participants in the Osteoporotic Fractures in Men Study in 
comparison with the 118 participants without diabetes.(81) Other authors did not find an 
association between BMAT volume and diabetes; yet, marrow adiposity was positively 
related to HbA1c levels and lower lipid unsaturation in patients with diabetes.(82, 83) 
Studies in mouse models showed consistently increased marrow adiposity;(84-86). The 
discrepancy between patients and experimental models could be attributed to the limited 
group size of clinical studies and the confounding influence of background factors, such 
as comorbidities and drug treatment.(60) 
Our group has performed an extensive investigation of the impact of diabetes on the 
general BM structure and function, including animal models and human subjects.(43, 
86-90) Results indicate that type 2 diabetes causes a profound remodelling of the 
marrow, including rarefaction of microvessels and sensory nerves, apoptotic 
pauperization of CD34 haematopoietic progenitor cells and fat accumulation (Figure 
2A). Morphometric analysis of the human BM showed a remarkable increase in the area 
covered by adipocytes compared with controls without diabetes, due to an increase in 
both adipocyte number and size (Figure 2B).(43, 87) The average adipocyte volume 
was 1.7-fold larger in patients with type 2 diabetes compared with non-diabetic controls. 
In a multiple regression model, the abundance of BMAT was associated with diabetes, 
independently of age, gender and body mass index (Table 2). (43, 87) This suggests 
that diabetes has an impact on BMAT accumulation that is autonomous from other major 
determinants of marrow adiposity. The mechanisms underpinning excess fat in the BM 




hyperinsulinemia, microangiopathy, neuropathy and adipokine-mediated processes 
could be implicated. 
Activation of aging mechanisms. The expansion of BMAT occurring in diabetic 
people is regarded as a facet of the whole-body accelerated senescence process.(91) 
On the other hand, BMAT aging could amplify senescence at systemic levels through 
direct endocrine mechanisms, but also indirectly impinging upon regenerative 
mechanisms presided by hematopoietic and mesenchymal stromal cells.(92) The 
intricate nature of this reciprocal interaction requires further investigation. Table 3 
summarizes the typical features of senescence in peripheral fat and BMAT. The 
chronological aging of adipocytes from peripheral depots has been defined as a 
propensity to undergo apoptosis, accumulate reactive oxygen species, (93) and 
manifest an inflammatory profile. (94-97) Moreover, aged adipocytes show increased 
levels of p53, p21 and p16, and a decrease in SIRT-1 protein compared to younger 
cells. (97-99) Studies in established obesity and type 2 diabetes indicated that the 
number of adipogenic progenitor cells is not altered, whereas signalling responsible 
for adipogenic differentiation is suppressed (98-102)  
In apparent contrast with peripheral fat, we found that in BM of diabetic patients 
preadipocytes expressed higher transcript levels of the differentiation markers 
C/EBPα, PPARγ, adiponectin, and fatty acid–binding protein 4 (FABP4) and were 
further stimulated to differentiate under the influence of mature adipocytes (see 
below). (Ferland-McCollough et al., 2018). It is therefore probable that newly formed 
adipocytes fill the space left by necrotic and apoptotic adipocytes.(43, 87)   In addition, 
BMAT secretes a unique repertoire of chemokines(103) A recent study comparing BM 
and peripheral adipocytes from the same healthy subject showed that the former 
express increased levels of pro-inflammatory molecules concomitant with an elevated 




diabetes. BM-adipocytes from diabetic patients secrete higher quantities of MCP-1, 
leptin, resistin, MMP2 and interferon-γ, but lower quantities of adiponectin.(43)  
Hyperinsulinemia and glycation. Insulin signaling role in regulation of mitochondrial 
function has been investigated in liver, muscle, or adipose tissue, but only marginally in 
BM adipocytes and pre-adipocytes. A recent report indicates that enhanced insulin 
signaling increases the activity of the mitochondrial oxidative phosphorylation system 
and production of reactive oxygen species in BM pre-adipocytes of obese subjects. 
(Tencerova, Frost et al., 2019) The authors posited that the insulin-mediated 
hypermetabolic status induces pre-adipocyte conversion to adipocytes but also 
senescence and pro-inflammatory phenotype.  
 RAGE, the receptor for advanced glycation end products, is a candidate inducer of 
BMAT. Deletion of RAGE prevents the upregulation of adipogenic factors induced by 
type 1 diabetes in BM stromal cells and their differentiation into adipocytes. (105) 
• Microangiopathy and hypoxia. The BM is considered a constitutively low-oxygen 
tension tissue, a characteristic instrumental in maintaining haematopoietic stem cells 
quiescence. Using two-photon phosphorescence lifetime microscopy, Spencer et al 
have determined the absolute pO2 of the BM.(106) The lowest pO2 (~9.9 mmHg, or 
1.3%) was found in deeper peri-sinusoidal regions; whereas the endosteal region, which 
is perfused by small arteries, was less hypoxic. In mice, constitutive BMAT is reportedly 
more abundant in the zone with higher vascular density while regulated BMAT is 
prevalent in the hypoxic zone.(107)  
 Jiang et al. have shown that extreme hypoxia enhanced adipogenic differentiation 
of BM stromal cells, through a mechanism involving the HIF-1A dependent activation of 
adipocyte-specific genes.(108) However, these findings are in contradiction with an 
earlier report showing no effect of hypoxia on differentiation.(109) In peripheral fat 




several inflammation-related adipokines as well as adipocyte degeneration and death 
with liberation of the lipid cargo.(110) However, to the best of our knowledge, this 
mechanism has not been explored in the BMAT. In BM of people and models with 
diabetes, we observed a remarkable association between microvascular rarefaction and 
BMAT accumulation, which indirectly supports the hypothesis of hypoxia being an 
inducer of adipogenesis.(43, 87) Nonetheless, the demonstration of a cause effect 
relationship between these phenomena warrants further investigation. 
• Neuropathy. The central nervous system is a key mediator of adipose tissue 
function through sympathetic adrenergic signalling. BM adipocytes are surrounded by 
neuronal fibers, with a density that increases from proximal to distal along the length of 
the tibia.(111, 112) Moreover, BMAT autonomic innervation shares common central 
pathways with peripheral adipose tissue. These include putative “command” neurons 
that may facilitate an interplay between the BM, BMAT and peripheral adipose 
tissue.(111) Several groups, including ours, have demonstrated the occurrence of 
sympathetic and nociceptive neuropathy in the BM of mice and humans with type 2 
diabetes, characterized by the dysfunctional release of neurokinins, such as substance 
P.(88, 113-115) This altered nociceptor signalling may contribute to BMAT 
accumulation. In line with this, substance P is capable of inducing lipid accumulation in 
3T3-L1 cells during their differentiation into adipocytes in response to a high 
concentration of glucose.(116) We confirmed the occurrence of sensory neuropathy in 
BM of type 1 diabetic mice and the possibility of preventing BM adverse remodelling 
with nerve growth factor gene therapy.(117) 
• Differentiation bias of BM stromal cells. Diabetes could also influence the fate 
of mesenchymal progenitors, the initial precursor and major source of adipocytes and 
osteoblasts, leading to an imbalance between adipogenesis and osteogenesis.(118) A 




of Notch2 may have a role in this imbalance.(119) We recently reported that BM stromal 
cells from type 2 diabetic patients have an increased propensity to differentiate into 
mature fat cells in an in-vitro adipogenesis assay as compared with cells from 
nondiabetic controls.(43) This was associated with the upregulation of PPAR and 
Adiponectin (ADIPOQ), which are master regulators of adipocyte differentiation and 
metabolism. The increase of adipogenic inducers observed in diabetic BMAT is an 
apparent contrast with findings from a study in elderly people, in which BM fat 
accumulation was attributed, at least in part, to repression of transcription factors in 
adipocyte precursors.(44) Understanding the difference between conditions that induce 
BMAT formation is crucial to develop personalised therapeutic strategies.  
 Interestingly, the secretome of diabetic adipocytes contains factors that can 
stimulate BM stromal cells specification to adipogenesis, thereby creating an 
incremental feedback loop by which existing fat stimulates other fat to accumulate. (43) 
To identify pathogenic components of the secretome, we measured the expression of 
multiple adipokines and cytokines in freshly harvested human BM adipocytes (Figure 
3A). The combined assessment of intracellular mRNA levels and secreted factors 
indicates diabetic BM adipocytes express and release leptin, CCL2, metalloproteinase 
2, and interferon- more abundantly than nondiabetic BM adipocytes.(43) Moreover, 
resistin, which is known to contribute to insulin resistance, was increased, whereas 
adiponectin, which promotes insulin sensitivity, was decreased in the conditioned 
medium of diabetic BM adipocytes. A STRING analysis of differentially regulated factors 
denoted they were associated in a functional network PPI enrichment p-value < 1.0e-16 
(Figure 3B). Among KEGG pathways hsa04933 AGE-RAGE signalling pathway was 




The pathogenic relevance of CCL2, a key notch in the network, was further explored 
by using the CCR2 antagonist RS504393. In-vitro, the antagonist abrogated the ability 
of the conditioned medium from BM adipocytes of type 2 diabetic patients to promote 
adipogenesis in BM stromal cells.(43) This was associated with inhibition of the 
transcription factor, CCL2-induced protein, which mediates inflammatory actions of 
CCL2 via sequential indunction of oxidative stress, endoplasmic reticulum stress and 
autophagy.(120) Likewise, in-vivo treatment of type 2 diabetic mice with RS504393 
reduced BM fat abundance and adipocyte quantities and size. Interestingly, RS504393 
treatment also improved the glycaemic control and reduced the quantity of epididymal 
fat, which is considered equivalent to white adipocytes of human VAT, but not inguinal 
fat, which is comparable in terms of location to the large gluteofemoral subcutaneous 
depot in humans.(43) This data suggests that blocking CCL2 signaling could be a viable 
option to blunt BMAT and VAT adiposopathy in type 2 diabetes.  
• Induction of adipogenic microRNA. MicroRNAs (miRNAs) are evolutionarily 
conserved small non-coding RNAs of ∼22 nucleotides in length involved in a range of 
pathophysiological processes. Several miRNAs have implicated in the regulation of 
adipocyte function, diabetes, obesity, and cardiovascular pathologies.(121) We found 
that five adipo-miRNAs were significantly upregulated and three downregulated in BM 
adipocytes from patients with type 2 diabetes (Figure 4A). Interestingly, the analysis of 
candidate targets showed all the downregulated miRNAs converge towards the CCL2 
pathway (Figure 4B). MiRNA-124a (-19.4-fold vs. ND, P<0.01) directly inhibits CCL2 
thereby regulating the fate of M2 tissue-resident macrophages,(122-124) and the 
suppression of FoxP3 Tregs.(125)  Likewise, miRNA-193b (-18.4-fold, P<0.01 vs. ND) 
and miRNA-126 (-6.1-fold vs. ND, P<0.05 vs. ND) inhibit CCL2 expression in adipocytes 





 Moreover, as illustrated in Figure 4B, three miRNAs that we found upregulated in 
BM adipocytes from type 2 diabetic patients, miRNA-15a, miRNA-16, and miRNA-223 
converge in inhibiting IKKα, a suppressor of the NF-κB pathway (127-130) Altogether, 
these data provide evidence for the activation proadipogenic and inflammatory signalling 
in the BM of diabetic patients and rodents. 
Review purpose 3: Therapeutic approaches to inhibit BM adiposity 
Restoring proper fat content in BM of diabetic patients may benefit hematopoiesis, bone 
strength, and metabolic homeostasis. In the next paragraphs, we will provide a brief 
prospect of available and new candidate treatments. Mechanisms underpinning the 
effect of the described therapies are also reported in the subheadings, if this was 
supported by robust experimental evidence. In fact, for several proposed treatments, 
only observational data are available, with insufficient understanding of the underpinning 
mode of action. In addition, given the difficulties in a direct appreciation of the amount 
of BMAT, the graded approach used in obesity is generally not applicable.  
• Metabolic control. There is a consensus on the fact that BMAT formation is affected 
by glycaemic control; nonetheless, further studies are needed to determine whether 
these effects are independent of insulin action. BM adiposity is directly related with 
serum glucose and HbA1c.(103) Improvement in the glycaemic control induced by 
gastric bypass surgery and pharmacological treatment is reportedly associated with 
reduced BM fat content.(131)  
 Glucagon-like peptide-1 (GLP-1) is an intestinal hormone implicated in the 
regulation of glucose homeostasis. Exendin-4, a stable GLP-1 analogue currently used 
for the treatment of type 2 diabetes, promotes adipocytic and osteoblastic differentiation 
by influencing the number of committed progenitors.(132) Exendin-4 also stimulates 
lipolysis without affecting osteoblast metabolic activity.(133) The effect of GLP-1 on 




 Thiazolidinediones such as troglitazone, rosiglitazone and pioglitazone are PPARγ 
agonists that improve glucose control in patients with type 2 diabetes by enhancing 
insulin sensitivity. Side effects include induction of adipogenesis, osteoporosis and 
lowering of blood counts. These effects could be partially reversed by the selective 
PPARγ antagonist bisphenol A diglycidyl ether.(134) 
• Parathyroid Hormone. Treatment with Parathyroid Hormone (PTH) promotes bone 
formation, which may be mediated by a shift in the differentiation fate of BM stromal cells 
from adipocytes toward osteoblasts.(135, 136) This mechanism is seemingly implicated 
in suppression of BMAT by PTH in ovariectomized mice. Nonetheless, PHT treatment 
in mice with type 1 diabetes increases trabecular bone mass and suppresses osteoblast 
apoptosis without reducing BMAT.(137)  
• Exercise regulation of BMAT. Exercise can burn BMAT according to research 
conducted by Steiner et al. (138) Using obese mice, the authors challenged the 
established concept of BMAT incapability to fuel energy during exercise. Two groups of 
mice were randomly allocated to be fed a normal diet (lean mice) and or a high-fat diet 
(obese mice) starting a month after birth. When they were four months old, half the mice 
in each group were offered to exercise using a running wheel for the next six weeks. As 
expected, the obese mice showed more and larger fat cells in their marrow. After 
exercising, both obese and lean mice had a significant reduction in the overall size of 
fat cells and the overall quantity of BMAT. There was however a remarkable difference 
in the number of BM adipocytes, which remained unchanged in lean mice but fell by 
more than half in exercised obese mice compared with sedentary obese mice. 
Additionally, exercise improved the thickness of bone, with this effect being more 
pronounced in obese mice. The authors speculated that BMAT was burned to generate 




Interestingly, exercise is effective in preventing the side effects of PPARγ 
agonists.(139) In mice, the PPARγ agonist rosiglitazone induced BMAT extension to the 
femoral diaphysis, while superimposing exercise suppressed BMAT accumulation, 
induced adipocytes browning, and supported  bone formation.(25)  
Observational studies comparing athletes and sedentary people, as well as 
interventional studies in children and older men confirm a benefit of exercise on BM 
adiposity.(140, 141) Moreover, prolonged bed rest increases BMAT and this could be 
inhibited by exercise.(142)  
• Caloric restriction. In a follow-up of the above study, the same group demonstrated 
that adding caloric restriction to exercise can be detrimental to the bone health. This 
time, the authors split mice into two groups: one given a regular diet and the other with 
30% less calories than the regular diet but with supplements of minerals and vitamins 
to match the content in the normal diet. Then, mice were assigned into sedentary and 
exercise subgroups, and monitored for 6 weeks. Interestingly, adding exercise to calorie 
restriction consistently reduced BMAT volume but also made bones more fragile.(143) 
Therefore, a balanced diet seems to be necessary to take full advantage from exercise.  
Studies in humans are contradictory regarding the effect of caloric restriction. Bosy-
Westphal et al investigated 55 premenopausal women and 12 men undergoing 12 
weeks of low-calorie diet, which was followed by return to the usual diet.(144) Results 
showed a reduction of fat mass and marrow adiposity (~4%) during the low-calorie diet 
and regain of body weight and marrow adiposity with return to the usual diet. In line with 
this, Vogt at al showed obese patients with type 2 diabetes had a significant weight loss 
that was accompanied by a 5% decrease in vertebral marrow adiposity.(145) However, 
other two studies on obese subjects did not show any effect of diet on BMAT, despite 




• Adipocyte dedifferentiation. Recent research has shown that adipocytes can 
dedifferentiate into fibroblast-like cells in-vitro and thus re-acquire proliferation and 
multipotent capacities. A physiological example is represented by the capacity of 
adipocytes in mammary glands to undergo lipid loss and acquire a preadipocyte-like cell 
phenotype during late pregnancy and lactation. The dedifferentiated cells can re-
differentiate to generate adipocytes during the involution of the gland after 
lactation.(148) However, an earlier study in rodents discounted the possibility that 
lactation is responsible for decreased adipocyte content in BM during post-partum.(149) 
Therefore, mechanisms activated during mammary gland dedifferentiation could be 
organ specific.  
• Targeting the inflammasome. Danger signals that accumulate during aging, obesity, 
and diabetes can trigger active IL-1 production by myeloid lineage cells through 
paracrine signaling by BM adipocytes.(150) Blocking the NLRP3 inflammasome with 
glybenclamide indeed, inhibited accumulation of myeloid-derived suppressor cells, and 
stimulated B lymphopoiesis in vitro.(72) Similarly, in mice, deletion of NLRP3 prevented 
the decline of T lymphopoiesis.(151) These findings and data from our recent study, 
showing a CCL2 antagonist halted BMAT accumulation and re-established the 
abundance of long-term haematopoietic stem cells in type 2 diabetic mice, suggest that 
targeting the inflammasome pathway could be an effective means to restore BM health 
in diabetes. (43)  Strategies to reduce the inflammasome activation diabetes could prove 
useful as a treatment to contrast the myelopoiesis/lymphopoiesis imbalance in patients 
with type 2 diabetes.(152, 153) 
• Senolytic agents. A breakthrough study from Kirkland’s group showed that 




elimination of senescent preadipocytes and increased lifespan in recipient mice.(154) 
The effect of such a radical treatment on BMAT needs to be demonstrated.  
• Miscellanea. Several bioactive molecules may stimulate osteogenic differentiation 
while inhibiting BM adipogenesis. For instance, resveratrol, a phytoalexin acting as a 
caloric mimetic, can contrast the adipogenic commitment of BM stromal cells,(155) and 
promote anti-aging functions on lipolysis, mitochondrial biogenesis and thermogenesis, 
in part through activation of SIRT1.(156) Vitamin D combined with genistein, quercetin, 
and resveratrol showed inhibitory effects on BMAT.(157) Puerarin, a phytoestrogen 
used in Chinese traditional medicine, in association with zinc supported BM stromal cells 
proliferation, and induced the expression of alkaline phosphatase, while decreasing 
BMAT mass.(158) Similar effects have been reported for genistein, epigallocatechin and 
various oxysterols; all of them being capable of inhibiting PPARγ expression and 
repressing adipogenic differentiation of BM stromal cells.(159-161) Strontium ranelate 
is used for the treatment osteoporosis; it also reportedly exerted a dose-dependent 
inhibitory effect on BM adipocyte differentiation and lipotoxicity within the BM 
environment.(162) In senescent mice, strontium ranelate treatment increased bone 
mass and reduced BMAT through stimulation of Wnt and NFATc/Maf pathways, and 
consequent inhibition of adipogenesis due to inhibition of PPARγ expression.(163) 
• Authors’ view regarding therapeutic intervention. Evidence from literature is not 
enough to determine when, how, and to which extent treating excess BMAT. Difference 
and even contraindication exist for the use of drugs that benefit the general metabolic 
control. Moreover, imaging techniques may not be available or justified on a cost-benefit 
basis to the general population. Surrogate molecular and cellular markers in peripheral 







Studies from our group and others clearly indicate that diabetes impinges upon the BM 
integrity, one major characteristic being the accumulation of fat and depletion of the 
vascular and hematopoietic niche. Excess BMAT goes in parallel with cardiovascular 
complications, suggesting possible causative relationship between these pathological 
processes. Several therapeutic options are available, and others may be developed 
soon as underpinning mechanisms of BM adiposopathy are unravelled. If BM 
adiposopathy can be halted or reversed, then next question is whether the empty space 
left by fat loss will be replaced by functional hematopoietic and stromal tissue or become 
a scar. Future research should address optimal windows for treatments in relation with 






















Figure 1: Characteristics of different fat depots. (A) Histology of white (WAT), 
brown (BAT), and bone marrow adipose tissue (BMAT). (B) Distribution of WAT, BAT 
and beige adipose tissue in mice and humans. (C) distribution of constitutive and 
inducible BMAT. 
 
Figure 2: Association of BMAT with vascular complications. (A) Histology of 
human BM from non-diabetic controls and type 2 diabetic patients with or without 
critical limb ischaemia. Relative proportion of fat increases in diabetes and even more 
in the case of associated limb ischaemia. (B) Shift of BM adipocyte (ADPC) toward 
larger sizes in type 2 diabetic patients.  
 
Figure 3: Alteration of the BMAT secretory phenotype in diabetes. (A) T2D 
modulates the expression and secretion of adipokines and cytokines in BM 
adipocytes. Bars graphs showing secreted factors in conditioned media from BM 
adipocytes of subjects without diabetes (ND) and with T2D, as assessed by ELISA. 
(B) Network analysis of secreted factors. 
 
Figure 4: microRNA profile of diabetic BM adipocytes. (A) differentially modulated 
microRNAs. (B) cartoon highlighting alterations in lipid flux, storage, and efflux and 








Table 1: Difference in modulation of adipogenesis in BMAT versus other depots. an 
up arrow indicates increased numbers of cells; and adown arrow indicates decreased 
numbers of cells 





High fat diet 
    
Methionine restriction  





















Table 2: BMAT abundance in type 2 diabetes 
 Controls T2D T2D+CLI 
Number 41 19 10 
Sex (Male) 24 12 6 





















T2D, Type 2 diabetes; CLI, Critical limb ischaemia. Values are mean±SEM with min-
max in parenthesis; *p<0.01 and **p<0.001 vs. Controls. Results of Covariance 













Table 3: Comparison of aging features in BM of diabetic patients and peripheral fat depots 
Peripheral fat senescence BMAT senescence in diabetes 
Senescent adipocytes present progressive changes 
with aging typically showing roundish shape, greater 
diameters, smaller peripheral nuclei and a large central 
lipid droplet.(166) 
Increased in BM adipocyte number and size. In our 
study, the average size was 4,487 ± 675 and 7,812 ± 
666 μm2 in subjects without or with diabetes, 
respectively, corresponding to a 1.74-fold increase. (43) 
Senescent preadipocytes/adipocytes produce more 
inflammatory cytokines, such as interleukin-6 (IL-6) and 
monocyte chemoattractant protein-1 (MCP-1/CCL2), 
and less anti-inflammatory cytokines, such as 
adiponectin. This associates with an increased 
infiltration of macrophages. Another feature of the so-
called senescence-associated secretory phenotype 
(SASP) is the secretion of extracellular matrix proteins, 
such as COL1α1 and MMP-11. Proinflammatory 
phenotype can be propagated to neighbouring cells.  
(94-96) 
BMAT secretes a unique repertoire of chemokines(103) 
A recent study comparing BM and peripheral adipocytes 
from the same healthy subject showed that the former 
express increased levels of pro-inflammatory molecules 
concomitant with an elevated generation of reactive 
oxygen species.(104) We showed BM-adipocytes from 
diabetic patients have upregulated levels of adipokines 
leptin, resistin TNF, and MCP-1, while IGF1, PEDF, 
IL18, adiponectin and angiopoietin are downregulated. 
Diabetic BM adipocytes secrete high quantities of MCP-
1, leptin, resistin, MMP2 and interferon-γ, but less 
adiponectin. They propagate the inflammatory 
phenotype to BM stromal cells. (43)  
In obese individuals with type 2 diabetes, SAT cells 
showed to have reduced proadipogenic signals, with 
downregulation of CCAAT/enhancer binding protein α 
(C/EBPα) and peroxisome proliferator-activated 
receptor gamma (PPARɣ) leading to larger fat cells, 
ectopic fat deposition and insulin resistance. (100-102) 
In contrast to peripheral adipocytes, diabetic BM-
preadipocytes expressed higher transcript levels of the 
differentiation markers C/EBPα PPARγ, adiponectin, 
and fatty acid–binding protein 4 (FABP4). (Ferland-
McCollough et al., 2018) 
Obesity is characterised by chronic low-grade 
inflammation with permanently increased oxidative 
stress. The number of apoptotic events is significantly 
higher in adipocytes and related with intracellular 
oxidative stress levels.(167) Oxidative stress reportedly 
Inhibits adipose expansion through suppression of 
lipogenic pathway.(93) 
Oxidative stress, assessed using the CM-H2DCFDA 
fluorophore, is increased in total BM cells together with 
p-H2AX (Ser139), a marker of double DNA strand 
breaks.(86, 87) 
Studies of hypertrophic obesity and diabetes indicate 
the number of adipogenic progenitor cells is not altered. 
Instead, a key mechanism for the impaired 
adipogenesis is an increased progenitor cell 
senescence, characterised by induction of BCL-2, BAX 
and LITAF, dysregulated p53 and P16ink4 resulting in 
inhibition of cell adipogenic differentiation. (98, 99) 
Stromal cells were reportedly not reduced in the BM of 
diabetic patients. Cell cycle was not assessed in 
preadipocytes. However, we could not find defects in 
the proliferation of BM preadipocytes from diabetic 
patients. In contrast, adipocyte precursors seem to be 
committed to adipogenic differentiation. It is therefore 
probable that new adipocytes fill the space left by 
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